Biomarkers and targeted systemic therapies in advanced non-small cell lung cancer.

ABSTRACT: The last decade has witnessed significant growth in therapeutic options for patients diagnosed with lung cancer. This is due in major part to our improved technological ability to interrogate the genomics of cancer cells, which has enabled the development of biologically rational anticancer agents. The recognition that lung cancer is not a single disease entity dates back many decades to the histological subclassification of malignant neoplasms of the lung into subcategories of small cell lung cancer (SCLC) and non-small cell lung cancer (NSCLC). While SCLC continues to be regarded as a single histologic and therapeutic category, the NSCLC subset has undergone additional subcategorizations with distinct management algorithms for specific histologic and molecular subtypes. The defining char

SUBMITTER: Kumar M 

PROVIDER: S-EPMC4637259 | biostudies-literature | 2015 Nov

REPOSITORIES: biostudies-literature